## John T Leppert

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2385064/publications.pdf

Version: 2024-02-01

103 4,239 29 62
papers citations h-index g-index

105 105 105 6476 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Organoid Modeling of the Tumor Immune Microenvironment. Cell, 2018, 175, 1972-1988.e16.	13.5	870
2	Phase II Study of Pomegranate Juice for Men with Rising Prostate-Specific Antigen following Surgery or Radiation for Prostate Cancer. Clinical Cancer Research, 2006, 12, 4018-4026.	3.2	428
3	RENAL CELL CARCINOMA 2005: NEW FRONTIERS IN STAGING, PROGNOSTICATION AND TARGETED MOLECULAR THERAPY. Journal of Urology, 2005, 173, 1853-1862.	0.2	320
4	Flexible Ureteroscopy and Laser Lithotripsy for Multiple Unilateral Intrarenal Stones. European Urology, 2009, 55, 1190-1197.	0.9	191
5	Prostate Magnetic Resonance Imaging Interpretation Varies Substantially Across Radiologists. European Urology Focus, 2019, 5, 592-599.	1.6	179
6	Hypoxia-Inducible Factor $1\hat{l}_{\pm}$ in Clear Cell Renal Cell Carcinoma. Clinical Cancer Research, 2007, 13, 7388-7393.	3.2	171
7	Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era. International Journal of Cancer, 2014, 134, 2245-2252.	2.3	114
8	Systematic evaluation of environmental and behavioural factors associated with all-cause mortality in the United States National Health and Nutrition Examination Survey. International Journal of Epidemiology, 2013, 42, 1795-1810.	0.9	109
9	Surveillance following radical or partial nephrectomy for renal cell carcinoma. Current Urology Reports, 2005, 6, 7-18.	1.0	108
10	Diabetic Severity and Risk of Kidney Stone Disease. European Urology, 2014, 65, 242-247.	0.9	96
11	Screening Rates for Primary Aldosteronism in Resistant Hypertension. Hypertension, 2020, 75, 650-659.	1.3	92
12	Utilization of Renal Mass Biopsy in Patients With Renal Cell Carcinoma. Urology, 2014, 83, 774-780.	0.5	85
13	Testing for Primary Aldosteronism and Mineralocorticoid Receptor Antagonist Use Among U.S. Veterans. Annals of Internal Medicine, 2021, 174, 289-297.	2.0	79
14	The Predictive Value of Inflammation-Related Peripheral Blood Measurements in Cancer Staging and Prognosis. Frontiers in Oncology, 2018, 8, 78.	1.3	73
15	Biologic differences between peripheral and transition zone prostate cancer. Prostate, 2015, 75, 183-190.	1.2	72
16	Trends and perioperative outcomes for laparoscopic and robotic nephrectomy using the National Surgical Quality Improvement Program (NSQIP) database 11 Financial Support: JTL is supported by Award no. DK089086 from the National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Urologic Oncology: Seminars and Original Investigations, 2014, 32, 473-479.	0.8	67
17	Prognostic relevance of capsular involvement and collecting system invasion in stage I and II renal cell carcinoma. BJU International, 2007, 99, 821-824.	1.3	66
18	Comparison of accuracy of 14â€, 18†and 20â€G needles in <i>exâ€vivo</i> renal mass biopsy: a prospective, blinded study. BJU International, 2010, 105, 940-945.	1.3	61

#	Article	IF	CITATIONS
19	The m <sup>6</sup> A RNA demethylase FTO is a HIF-independent synthetic lethal partner with the VHL tumor suppressor. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 21441-21449.	3.3	56
20	Incident CKD after Radical or Partial Nephrectomy. Journal of the American Society of Nephrology: JASN, 2018, 29, 207-216.	3.0	55
21	Diabetes Severity, Metabolic Syndrome, and the Risk of Erectile Dysfunction. Journal of Sexual Medicine, 2013, 10, 3102-3109.	0.3	52
22	Intraoperative Optical Biopsy during Robotic Assisted Radical Prostatectomy Using Confocal Endomicroscopy. Journal of Urology, 2016, 195, 1110-1117.	0.2	48
23	The Harms of Overdiagnosis and Overtreatment in Patients with Small Renal Masses: A Mini-review. European Urology Focus, 2019, 5, 943-945.	1.6	43
24	A Protective Role for Androgen Receptor in Clear Cell Renal Cell Carcinoma Based on Mining TCGA Data. PLoS ONE, 2016, 11, e0146505.	1.1	42
25	A Pilot Study of <i>In Vivo</i> Confocal Laser Endomicroscopy of Upper Tract Urothelial Carcinoma. Journal of Endourology, 2015, 29, 1418-1423.	1.1	40
26	S100A10 Is a Critical Mediator of GAS6/AXL–Induced Angiogenesis in Renal Cell Carcinoma. Cancer Research, 2019, 79, 5758-5768.	0.4	39
27	Carbonic anhydrase IX and the future of molecular markers in renal cell carcinoma. BJU International, 2005, 96, 281-285.	1.3	36
28	Adjuvant therapy of renal cell carcinoma: patient selection and therapeutic options. BJU International, 2005, 96, 483-488.	1.3	35
29	Clinical, Molecular, and Genetic Correlates of Lymphatic Spread in Clear Cell Renal Cell Carcinoma. European Urology, 2012, 61, 888-895.	0.9	29
30	Implants of noninvasive papillary urothelial carcinoma in peritoneum and ileocolonic neobladder: Support for "seed and soil―hypothesis of bladder recurrence. Urology, 2006, 67, 746-750.	0.5	28
31	Ultra-Low-Dose CT: An Effective Follow-Up Imaging Modality for Ureterolithiasis. Journal of Endourology, 2020, 34, 139-144.	1.1	27
32	Analysis of Primary Hyperparathyroidism Screening Among US Veterans With Kidney Stones. JAMA Surgery, 2020, 155, 861.	2.2	26
33	Contemporary Use of Partial Nephrectomy: Are Older Patients With Impaired Kidney Function Being Left Behind?. Urology, 2017, 100, 65-71.	0.5	25
34	A Temporal Examination of Platelet Counts as a Predictor of Prognosis in Lung, Prostate, and Colon Cancer Patients. Scientific Reports, 2018, 8, 6564.	1.6	25
35	Overall Survival in Patients with Localized Prostate Cancer in the US Veterans Health Administration: Is PIVOT Generalizable?. European Urology, 2016, 70, 227-230.	0.9	24
36	Unplanned Emergency Department Visits and Hospital Admissions Following Ureteroscopy: Do Ureteral Stents Make a Difference?. Urology, 2018, 117, 44-49.	0.5	23

#	Article	IF	CITATIONS
37	Payer Type, Race/Ethnicity, and the Timing of Surgical Management of Urinary Stone Disease. Journal of Endourology, 2019, 33, 152-158.	1.1	22
38	Redefining the Stone Belt: Precipitation Is Associated with Increased Risk of Urinary Stone Disease. Journal of Endourology, 2017, 31, 1203-1210.	1.1	21
39	External Validation of the Prostate Cancer Specific Comorbidity Index: A Claims Based Tool for the Prediction of Life Expectancy in Men with Prostate Cancer. Journal of Urology, 2019, 202, 518-524.	0.2	20
40	The role of molecular markers in the staging of renal cell carcinoma. BJU International, 2007, 99, 1208-1211.	1.3	17
41	Comparative Effectiveness of Non-cisplatin First-line Therapies for Metastatic Urothelial Carcinoma: Phase 2 IMvigor210 Study Versus US Patients Treated in the Veterans Health Administration. European Urology Oncology, 2019, 2, 12-20.	2.6	17
42	The implications of baseline boneâ€health assessment at initiation of androgenâ€deprivation therapy for prostate cancer. BJU International, 2018, 121, 558-564.	1.3	16
43	Biochemical Measures of Diabetes are Not Independent Predictors of Urinary Incontinence in Women. Journal of Urology, 2015, 194, 1668-1674.	0.2	15
44	Nanoparticle-enabled innate immune stimulation activates endogenous tumor-infiltrating T cells with broad antigen specificities. Proceedings of the National Academy of Sciences of the United States of America, 2021, $118$ , .	3.3	14
45	Twenty-Four Hour Urine Testing and Prescriptions for Urinary Stone Disease–Related Medications in Veterans. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 1773-1780.	2.2	12
46	Urinary Stone Disease in Pregnancy: A Claims Based Analysis of 1.4 Million Patients. Journal of Urology, 2020, 203, 957-961.	0.2	12
47	The Research Implications of Prostate Specific Antigen Registry Errors: Data from the Veterans Health Administration. Journal of Urology, 2018, 200, 541-548.	0.2	11
48	Osteoporosis, Fractures, and Bone Mineral Density Screening in Veterans With Kidney Stone Disease. Journal of Bone and Mineral Research, 2020, 36, 872-878.	3.1	11
49	Open surgical management of renal cell carcinoma in the era of minimally invasive kidney surgery. BJU International, 2005, 96, 1268-1274.	1.3	10
50	Defining the Rate of Negative Ureteroscopy in the General Population Treated for Upper Tract Urinary Stone Disease. Journal of Endourology, 2017, 31, 266-271.	1.1	10
51	Development of a DNA Methylation–Based Diagnostic Signature to Distinguish Benign Oncocytoma From Renal Cell Carcinoma. JCO Precision Oncology, 2020, 4, 1141-1151.	1.5	10
52	Urinary Stone Disease in Pregnancy: Current Management Practices in a Large National Cohort. Urology, 2020, 142, 60-64.	0.5	10
53	De-implementation of low value castration for men with prostate cancer: protocol for a theory-based, mixed methods approach to minimizing low value androgen deprivation therapy (DeADT). Implementation Science, 2018, 13, 144.	2.5	9
54	Life expectancy estimates for patients diagnosed with prostate cancer in the Veterans Health Administration. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 734.e1-734.e10.	0.8	9

#	Article	IF	CITATIONS
55	The Urine Albumin-to-Creatinine Ratio and Kidney Function after Nephrectomy. Journal of Urology, 2020, 204, 231-238.	0.2	9
56	Accuracy of Prostate-Specific Antigen Values in Prostate Cancer Registries. Journal of Clinical Oncology, 2016, 34, 3586-3587.	0.8	8
57	Prevalence of twenty-four hour urine testing in Veterans with urinary stone disease. PLoS ONE, 2019, 14, e0220768.	1.1	8
58	Removing Race from eGFR calculations: Implications for Urologic Care. Urology, 2022, 162, 42-48.	0.5	8
59	Development and Validation of an Interpretable Artificial Intelligence Model to Predict 10-Year Prostate Cancer Mortality. Cancers, 2021, 13, 3064.	1.7	8
60	Interaction between race and prostate cancer treatment benefit in the Veterans Health Administration. Cancer, 2021, 127, 3985-3990.	2.0	8
61	Crowdsourced Assessment of Ureteroscopy with Laser Lithotripsy Video Feed Does Not Correlate with Trainee Experience. Journal of Endourology, 2019, 33, 42-49.	1.1	7
62	Laboratoryâ€wide association study of survival with prostate cancer. Cancer, 2021, 127, 1102-1113.	2.0	6
63	Evaluation of Patient Treatment Preferences for 15 to 20 mm Kidney Stones: A Conjoint Analysis. Journal of Endourology, 2021, 35, 706-711.	1.1	6
64	Using an Automated Electronic Health Record Score To Estimate Life Expectancy In Men Diagnosed With Prostate Cancer In The Veterans Health Administration. Urology, 2021, 155, 70-76.	0.5	6
65	Significance of gene expression analysis of renal cell carcinoma. Expert Review of Anticancer Therapy, 2006, 6, 293-299.	1.1	5
66	Perspective: Beyond the genome. Nature, 2016, 537, S105-S105.	13.7	5
67	Performance of multiparametric MRI appears better when measured in patients who undergo radical prostatectomy. Research and Reports in Urology, 2018, Volume 10, 233-235.	0.6	5
68	Kidney Stone Events Following Parathyroidectomy vs Nonoperative Management for Primary Hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e2801-e2811.	1.8	5
69	The sensitivity of testosterone immunoassays and their role in monitoring antiandrogen therapy. Urologic Oncology: Seminars and Original Investigations, 2006, 24, 277-278.	0.8	4
70	Ethical Pitfalls When Estimating Life Expectancy for Patients with Prostate Cancer. Journal of Urology, 2018, 200, 709-711.	0.2	4
71	Postmarketing Analysis of Sipuleucel-Tâ€"The Importance of Real-World Data. JAMA Network Open, 2019, 2, e199233.	2.8	4
72	Applying the PRECISION approach in biopsy na $\tilde{A}$ -ve and previously negative prostate biopsy patients. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 530.e19-530.e24.	0.8	4

#	Article	IF	Citations
73	Spinal anesthesia increases the rate of opioid-free recovery after transurethral urologic surgery. Journal of Clinical Anesthesia, 2020, 60, 109-110.	0.7	4
74	Twenty-four-hour Urine Testing and Urinary Stone Disease Recurrence in Veterans. Urology, 2022, 159, 33-40.	0.5	4
75	Optical biopsy of penile cancer with in vivo confocal laser endomicroscopy. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 809.e1-809.e8.	0.8	3
76	Characterising potential bone scan overuse amongst men treated with radical prostatectomy. BJU International, 2019, 124, 55-61.	1.3	3
77	Postoperative opioid-free ureteroscopy discharge: A quality initiative pilot protocol. Current Urology, 2021, 15, 176-180.	0.4	3
78	Risk of Postpartum Urinary Stone Disease in Women with History of Urinary Stone Disease During Pregnancy. Journal of Endourology, 2022, 36, 138-142.	1.1	3
79	Clinical laboratory tests associated with survival in patients with metastatic renal cell carcinoma: A Laboratory Wide Association Study (LWAS). Urologic Oncology: Seminars and Original Investigations, 2022, 40, 12.e23-12.e30.	0.8	3
80	Facility-Level Variation in Dialysis Use and Mortality Among Older Veterans With Incident Kidney Failure. JAMA Network Open, 2021, 4, e2034084.	2.8	3
81	Association of 152 Biomarker Reference Intervals with All-Cause Mortality in Participants of a General United States Survey from 1999 to 2010. Clinical Chemistry, 2021, 67, 500-507.	1.5	3
82	Preclinical Testing of a Combination Stone Basket and Ureteral Balloon to Extract Ureteral Stones. Journal of Endourology, 2018, 32, 96-99.	1.1	2
83	Association between PSA values and surveillance quality after prostate cancer surgery. Cancer Medicine, 2019, 8, 7903-7912.	1.3	2
84	Diabetes Medications, Prostate-Specific Antigen Values, and the Chemoprevention of Prostate Cancer. JAMA Network Open, 2019, 2, e1914644.	2.8	2
85	Multiregion Quantification of Extracellular Signal-regulated Kinase Activity in Renal Cell Carcinoma. European Urology Oncology, 2020, 3, 360-364.	2.6	2
86	Operating room preparedness for active shooter events. Surgery, 2020, 167, 510-511.	1.0	2
87	Association of Parathyroidectomy With 5-Year Clinically Significant Kidney Stone Events in Patients With Primary Hyperparathyroidism. Endocrine Practice, 2021, 27, 948-955.	1.1	2
88	Renal Morbidity Following Radical Cystectomy in Patients with Bladder Cancer. European Urology Open Science, 2022, 35, 29-36.	0.2	2
89	Predicting Response to Interleukin-2 Therapy Among Patients with Renal Cell Carcinoma. Journal of Immunotherapy, 2005, 28, 427-429.	1.2	1
90	Determining the prognosis of patients with renal cell carcinoma: is it time for a re-evaluation?. Nature Reviews Urology, 2006, 3, 510-511.	1.4	1

#	Article	IF	CITATIONS
91	Re: Brandon A. Mahal, David D. Yang, Natalie Q. Wang, et al. Clinical and Genomic Characterization of Low–Prostate-specific Antigen, High-grade Prostate Cancer. Eur Urol 2018;74:146–54. European Urology, 2018, 74, e110-e111.	0.9	1
92	Costs of Robotic-Assisted Radical Prostatectomy 1 Year After Surgery. JAMA Network Open, 2021, 4, e212548.	2.8	1
93	In Search of Clinical Biomarkers of Response to Checkpoint Inhibitor Therapy in Renal Cell Carcinoma. JAMA Network Open, 2021, 4, e2035120.	2.8	1
94	Reply. Urology, 2014, 83, 779-780.	0.5	0
95	Editorial Comment. Urology, 2014, 83, 1291-1292.	0.5	O
96	Editorial Comment. Urology, 2015, 86, 899.	0.5	0
97	Editorial Comment. Urology, 2017, 100, 156-157.	0.5	O
98	Applying Precision Oncology to Renal Cell Carcinoma: Emerging Challenges. European Urology, 2017, 72, 565-566.	0.9	0
99	Minimizing the Cost of Treating Asymptomatic Ureterolithiasis. Urology Practice, 2018, 5, 172-179.	0.2	O
100	Following Up on an Improperly Drawn Screening Test: The PSA Dilemma. American Journal of Medicine, 2021, 134, e145-e146.	0.6	0
101	AUTHOR REPLY. Urology, 2021, 155, 76.	0.5	0
102	Staging of Renal Cell Carcinoma. , 2008, , 41-52.		0
103	Dual X-ray Absorptiometry Screening for Men Receiving Androgen Deprivation Therapy—Hiding in Plain (Film) Sight. JAMA Network Open, 2022, 5, e225439.	2.8	O